Lisa M. Holle, PharmD, BCOP, FHOPA

New developments in cancer treatment require medication experts-here's how you can become that expert.

Here: an overview of atezolizumab, the first new drug in two decades for bladder cancer and now approved for NSCLC.

New drug review

FDA approved ixazomib (Ninlaro, Takeda) in combination with lenalidomide and dexamethasone

Rolapitant is a novel NK1 receptor antagonist that maintains >90% receptor binding up to five days after a single 180-mg dose.